Clinical applications of antimicrobial peptides (AMPs): where do we stand now? M Divyashree, MK Mani, D Reddy, R Kumavath, P Ghosh, V Azevedo, ... Protein and peptide letters 27 (2), 120-134, 2020 | 107 | 2020 |
Lanatoside C induces G2/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways D Reddy, R Kumavath, P Ghosh, D Barh Biomolecules 9 (12), 792, 2019 | 89 | 2019 |
Anticancer and antiviral properties of cardiac glycosides: a review to explore the mechanism of actions D Reddy, R Kumavath, D Barh, V Azevedo, P Ghosh Molecules 25 (16), 3596, 2020 | 61 | 2020 |
Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers D Reddy, R Kumavath, TZ Tan, DR Ampasala, AP Kumar Life sciences 241, 117147, 2020 | 53 | 2020 |
Anti-quorum sensing and anti-biofilm activity of 5-hydroxymethylfurfural against Pseudomonas aeruginosa PAO1: Insights from in vitro, in vivo and in silico studies J Rajkumari, S Borkotoky, D Reddy, SK Mohanty, R Kumavath, A Murali, ... Microbiological research 226, 19-26, 2019 | 50 | 2019 |
Mosloflavone attenuates the quorum sensing controlled virulence phenotypes and biofilm formation in Pseudomonas aeruginosa PAO1: In vitro, in vivo and in silico approach S Hnamte, P Parasuraman, S Ranganathan, DR Ampasala, D Reddy, ... Microbial pathogenesis 131, 128-134, 2019 | 44 | 2019 |
Strophanthidin attenuates MAPK, PI3K/AKT/mTOR, and Wnt/β-catenin signaling pathways in human cancers D Reddy, P Ghosh, R Kumavath Frontiers in oncology 9, 1469, 2020 | 43 | 2020 |
Inhibition of microbial quorum sensing mediated virulence factors by Pestalotiopsis sydowiana P Parasuraman, B Devadatha, VV Sarma, S Ranganathan, DR Ampasala, ... Journal of Microbiology and Biotechnology 30 (4), 571, 2020 | 23 | 2020 |
Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions DS Reddy, S Sarvesh, B Farran, GP Nagaraju, BF El-Rayes Cytokine & Growth Factor Reviews, 2023 | 5 | 2023 |
LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition P Malvi, DS Reddy, R Kumar, S Chava, S Burela, K Parajuli, X Zhang, ... Oncogene 42 (18), 1478-1491, 2023 | 3 | 2023 |
UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress R Dutta, P Guruvaiah, KK Reddi, S Bugide, DS Reddy Bandi, ... NAR cancer 4 (4), zcac035, 2022 | 3 | 2022 |
Evaluation of a novel Pan-RAS/β-Catenin inhibitor, ADT-030, for treatment of pancreatic cancer. GA Piazza, RDS Bandi, PN Ganji, JB Foote, AB Keeton, TE Mattox, ... Journal of Clinical Oncology 42 (16_suppl), e15084-e15084, 2024 | | 2024 |
A potent and selective pan-RAS inhibitor, ADT-1004, targeting complex KRAS mutations for pancreatic cancer. GA Piazza, RDS Bandi, PN Ganji, JB Foote, AB Keeton, TE Mattox, ... Journal of Clinical Oncology 42 (16_suppl), e15085-e15085, 2024 | | 2024 |
ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models S Bugide, DS Reddy, P Malvi, R Gupta, N Wajapeyee Iscience 27 (5), 2024 | | 2024 |
Development of first in class zip code drug conjugate in pancreatic ductal adenocarcinoma M Cinar, P Ganji, A Pisarev, L Martinez-Medina, DS Bandi, PK Puvvula, ... Cancer Research 84 (6_Supplement), 3211-3211, 2024 | | 2024 |
ADT-1004: A promising pan-RAS inhibitor for targeting KRAS mutations in pancreatic ductal adenocarcinoma DSR Bandi, PN Ganji, S Sarvesh, Y Maxuitenko, JB Foote, AB Keeton, ... Cancer Research 84 (6_Supplement), 5915-5915, 2024 | | 2024 |
Novel Pan-RAS inhibitor ADT-007: A unique mechanism of antitumor selectivity in pancreatic and colorectal carcinoma models J Wang, AB Keeton, S Ramesh, P Johnson, YY Maxuitenko, JB Foote, ... Cancer Research 84 (6_Supplement), 3323-3323, 2024 | | 2024 |
Abstract LB_B26: Efficacy and tolerability of a novel pan-RAS inhibitor with a unique mechanism of selectivity in mouse models of pancreatic cancer AB Keeton, YY Maxuitenko, JB Foote, CH Huang, KL Berry, K Fadlalla, ... Molecular Cancer Therapeutics 22 (12_Supplement), LB_B26-LB_B26, 2023 | | 2023 |